Related Experiment Video
Updated: Jul 5, 2025
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
NCCN Guidelines® Insights: Merkel Cell Carcinoma, Version 1.2024
Chrysalyne D Schmults1, Rachel Blitzblau2, Sumaira Z Aasi3
1Dana-Farber/Brigham and Women's Cancer Center.
Abstract:
The NCCN Guidelines for Merkel Cell Carcinoma (MCC) provide recommendations for diagnostic workup, clinical stage, and treatment options for patients. The panel meets annually to discuss updates to the guidelines based on comments from expert review from panel members, institutional review, as well as submissions from within NCCN and external organizations. These NCCN Guidelines Insights focus on the introduction of a new page for locally advanced disease in the setting of clinical node negative status, entitled "Clinical N0 Disease, Locally Advanced MCC." This new algorithm page addresses locally advanced disease, and the panel clarifies the meaning behind the term "nonsurgical" by further defining locally advanced disease. In addition, the guideline includes the management of in-transit disease and updates to the systemic therapy options.
Insights
The National Comprehensive Cancer Network (NCCN) updated Merkel cell carcinoma (MCC) guidelines, introducing new criteria for locally advanced disease and clarifying treatment options. These updates enhance diagnostic and therapeutic strategies for MCC patients.
Area of Science:
- Oncology
- Dermatology
- Medical Guidelines
Background:
- Merkel cell carcinoma (MCC) is a rare but aggressive skin cancer.
- Current NCCN Guidelines require annual updates to reflect the latest research and clinical insights.
- Expert review and external submissions inform guideline revisions.
Purpose of the Study:
- To detail recent updates to the NCCN Guidelines for Merkel cell carcinoma (MCC).
- To introduce a new algorithmic page for "Clinical N0 Disease, Locally Advanced MCC."
- To clarify definitions and management strategies for locally advanced and in-transit MCC.
Main Methods:
- Annual review and revision process by the NCCN panel.
- Incorporation of expert feedback and external submissions.
- Development of new guideline content and updates to existing sections.
Main Results:
- Introduction of a new section for "Clinical N0 Disease, Locally Advanced MCC."
- Clarification of the term "nonsurgical" in the context of locally advanced MCC.
- Inclusion of updated management for in-transit disease and systemic therapy options.
Conclusions:
- The updated NCCN Guidelines provide refined recommendations for diagnosing and treating MCC.
- The new guidance addresses specific challenges in managing locally advanced and in-transit MCC.
- These revisions aim to optimize patient care through evidence-based strategies.
